Print Page | Contact Us | Report Abuse | Sign In | Join
Latest Medical Marijuana News: Latest News

Leafly Announces Partnership With the American Medical Marijuana Physicians Association

Tuesday, December 10, 2019   (0 Comments)
Share |

Leafly and AMMPA will work together on event programming and online education for physicians
December 10, 2019 09:00 AM Eastern Standard Time

SEATTLE--(BUSINESS WIRE)--Leafly, the world’s leading cannabis resource, today announced a strategic partnership with the American Medical Marijuana Physicians Association (AMMPA), the world’s largest physician-based cannabis association, to empower doctors to provide cannabis-based care to patients and better connect patients with licensed cannabis physicians. The partnership reflects the rise in demand for cannabinoid medicine as 33 U.S. states have now legalized cannabis use for certain medical conditions and more than 90% of the American public supports federal legalization of cannabis for both medical and recreational use.

“At Leafly, we are passionate about the potential of cannabis to improve the lives of patients. From veterans managing PTSD to promising signs that medical cannabis can curb opioid use, there is no shortage of ways cannabis can play a role in treating complex and chronic conditions,” said Tim Leslie, CEO of Leafly. “We are honored to join forces with AMMPA to help doctors learn more about the power of cannabis and empower them with information to give them more confidence incorporating cannabis into patient care.”

As part of the partnership, Leafly will include AMMPA membership as part of a subscription plan for doctors that maintain a presence on Leafly. Leafly and AMMPA will also partner on upcoming events that advance medical cannabis education and physician advocacy, including the AMMPA Annual Conference attended by hundreds of physicians every year. To empower doctor education, Leafly and AMMPA will work together on the development of an online learning course that covers topics such as the endocannabinoid system, dosage and delivery, and the chemical components of cannabis like terpenes and cannabinoids.

“The medical community is increasingly embracing cannabis as an effective and versatile option to help improve patient outcomes and treatment. By teaming up with Leafly, we can work together to provide doctors the tools and information they need to feel confident bringing cannabis into their practice and helping patients understand how this powerful plant may benefit them,” said Dr. Mark Chaet, president of AMMPA.

Learn more about Leafly’s partnership with AMMPA, find medical cannabis providers near you, and explore Leafly subscriptions and AMMPA memberships for licensed cannabis doctors.


As the world’s largest cannabis information resource, Leafly helps people discover, find, and buy cannabis and empowers cannabis businesses to attract and retain loyal customers through advertising and technology services. Learn more at or download the five-star rated Leafly mobile app.


The American Medical Marijuana Physicians Association is the world’s largest physician-based cannabis association, focusing on providing physicians and healthcare professionals with the resources they need to safely and effectively utilize medical marijuana recommendations as an alternative treatment modality for their patients. Learn more at

Hannah Staton

Savara Hastings
(321) 917-3212


Copyright © 2016-2020 American Medical Marijuana Physicians Association

Disclaimer: The American Medical Marijuana Physicians Association does not publish membership information. Our goal is to ensure that community physicians have the tools and resources they need to safely and effectively recommend medical marijuana as a last resort alternative treatment. Physicians should utilize this alternative recommendation based on evidence when available and always educate the patient on potential risks and other treatment options. The American Medical Marijuana Physicians Association supports the need for more research into cannabinoid medicine as more high quality studies are needed. By accessing any page on this site you agree to the Site Terms and Conditions of Use.